S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:KTRA

Kintara Therapeutics (KTRA) Stock Price, News & Analysis

$0.10
+0.01 (+10.64%)
(As of 03/28/2024 ET)
Today's Range
$0.10
$0.11
50-Day Range
$0.08
$0.14
52-Week Range
$0.08
$5.98
Volume
32.16 million shs
Average Volume
12.26 million shs
Market Capitalization
$4.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Kintara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Kintara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.48) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.13 out of 5 stars

KTRA stock logo

About Kintara Therapeutics Stock (NASDAQ:KTRA)

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

KTRA Stock Price History

KTRA Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Kintara Therapeutics Bounces Back
Kintara Therapeutics Inc (KTRA)
MyMD Pharmaceuticals Inc (0A8D)
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Kintara Therapeutics Inc (3DMA.BE)
Kintara Therapeutics Inc KTRA
Kintara Therapeutics Non-GAAP EPS of -$9.27
KTRA - Kintara Therapeutics, Inc.
See More Headlines
Receive KTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KTRA
Employees
2
Year Founded
N/A

Profitability

Net Income
$-14,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($5.86) per share

Miscellaneous

Free Float
37,359,000
Market Cap
$4.06 million
Optionable
Not Optionable
Beta
0.59
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Jeffrey A. Bacha B.Sc. (Age 56)
    M.B.A., Founder
  • Mr. Greg A. Johnson
    Acting Head of Operations

KTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kintara Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KTRA shares.
View KTRA analyst ratings
or view top-rated stocks.

How have KTRA shares performed in 2024?

Kintara Therapeutics' stock was trading at $0.1696 at the beginning of 2024. Since then, KTRA shares have decreased by 38.7% and is now trading at $0.1040.
View the best growth stocks for 2024 here
.

When is Kintara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KTRA earnings forecast
.

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its earnings results on Wednesday, February, 14th. The company reported ($0.24) earnings per share for the quarter.

When did Kintara Therapeutics' stock split?

Kintara Therapeutics's stock reverse split on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

How do I buy shares of Kintara Therapeutics?

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KTRA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners